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Abstract 30 
In the consequence of emerging number of vulvovaginitis caused by azole-resistant and 31 
biofilm-forming Candida species, the fast and efficient treatment of this infection has become 32 
challenging. The problem is further exacerbated by the severe side-effects of azoles as long-33 
term use medications in the recurrent form. There is therefore an increasing demand for novel 34 
and safely applicable effective antifungal therapeutic strategies. The small, cysteine-rich and 35 
cationic antifungal proteins from filamentous ascomycetes are potential candidates as they 36 
inhibit the growth of several Candida spp. in vitro; however no information is available about 37 
their in vivo antifungal potency against yeasts. In the present study we investigated the 38 
possible therapeutic application of one of their representatives in the treatment of 39 
vulvovaginal candidiasis, the Neosartorya fischeri antifungal protein 2 (NFAP2). NFAP2 40 
inhibited the growth of a fluconazole (FLC)-resistant Candida albicans strain isolated from 41 
vulvovaginal infection, and it was effective against both planktonic cells and biofilm in vitro. 42 
We observed that the fungal cell killing activity of NFAP2 is connected to its pore-forming 43 
ability in the cell membrane. NFAP2 did not exert cytotoxic effects on primary human 44 
keratinocytes and dermal fibroblasts at the minimal inhibitory concentration in vitro. In vivo 45 
murine vulvovaginitis model experiments showed that NFAP2 significantly decreases the cell 46 
number of the FLC-resistant C. albicans, and the combined application with FLC enhances 47 
the efficacy. These results suggest that NFAP2 provides a feasible base for the development 48 
of a fundamental new, safely applicable mono- or polytherapeutic topical agent in the 49 
treatment of superficial candidiasis. 50 
 51 
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Introduction 55 
Candida spp. belong to the normal human flora under the control of a sensitive and well-56 
regulated balance mechanism between the fungus and the host-defense system. If this 57 
mechanism is disturbed by physiological or non-physiological changes, Candida can 58 
overgrow the dermal and mucosal surfaces in healthy individuals. One of these symptoms is 59 
the vulvovaginal candidiasis (VVC), when Candida infects the surface of vaginal and vulvar 60 
mucosa (1). VVC is estimated to be the most common fungal infection in a number of 61 
countries (2), and has been considered to be an important worldwide public health problem by 62 
the World Health Organization (3). VVC affects ~75% of adult women at least once in their 63 
lifetime, ~15% of the cases are asymptomatic, and ~10% are recurrent (RVVC) which means 64 
more than four infection episodes per year in the absence of predisposing factors. Although 65 
VVC is not associated with mortality, it causes discomfort, pain, and social embarrassment 66 
which impair sexual and affective relationships, and work performance. Untreated VVC can 67 
lead to severe complications, such as vaginitis and penitis if it is transferred to the male 68 
partner; and as a consequence pelvic inflammation, infertility, ectopic pregnancy, pelvic 69 
abscess, spontaneous abortion and menstrual disorders can occur (1). 70 
Candida albicans is still the most common VVC associated yeast in most countries. However, 71 
epidemiology surveys from the last 15 years have demonstrated an increasing prevalence of 72 
non-albicans Candida (NAC) species (1). The recommended treatment in the US for 73 
uncomplicated C. albicans VVC is the vaginal application of nystatin or azole-based topical 74 
agents, but considering the personal preference, a single oral dose of 150 mg fluconazole 75 
(FLC) is suggested alternatively. For severe acute cases such as RVVC, 150 mg FLC, given 76 
every 72 hours for a total of two or three doses, is recommended for six months (4, 5). This 77 
long-term FLC use may cause severe side effects in the host (e.g. liver toxicity) and promote 78 
the development of a resistance mechanism in the fungus (6). Susceptibility data indicate a 79 
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continuous increase in the number of VVC-related and FLC-resistant C. albicans isolates (2, 80 
7). The development of resistance mechanism is connected to the biofilm-forming ability of 81 
the fungus. Namely, C. albicans is able to adhere to the surface of vaginal epithelium and 82 
form a complex three-dimensional structure of fungal cell agglomerates with reduced 83 
susceptibility to azoles and less sensitivity to the killing mechanisms of the host immune 84 
system resulting in RVVC frequently (4). Therefore, nowadays the fast and efficient treatment 85 
of RVVC becomes more and more challenging, and novel, safely applicable antifungal 86 
strategies are needed with high efficiency against Candida biofilms. 87 
In vitro susceptibility data suggest that the small molecular weight, cysteine-rich and cationic 88 
antifungal proteins secreted by filamentous ascomycetes (crAFP) are potential therapeutic 89 
candidates to fight against Candida infections (8-13). In our previous study we already 90 
demonstrated that one of their representatives, the Neosartorya fischeri antifungal protein 2 91 
(NFAP2) effectively inhibits the growth of clinically relevant Candida spp. in the 92 
standardized clinical susceptibility Clinical and Laboratory Standards Institute (CLSI) M27-93 
A3 testing method, and interacts synergistically with FLC in vitro (12). These observations 94 
propose the in vivo efficacy and potential applicability of NFAP2 as mono- or polytherapeutic 95 
agent in anti-Candida therapy. 96 
To prove this assumption, in the present study we investigated the in vivo applicability of 97 
NFAP2 in the treatment of VVC. First of all, we determined the in vitro cell-killing efficacy 98 
and antifungal mechanism of NFAP2 against a FLC-resistant and biofilm-forming C. albicans 99 
strain isolated from human VVC, before testing the in vitro cytotoxicity of NFAP2 on primary 100 
human keratinocytes (HKC) and dermal fibroblasts (HDF). Based on the promising in vitro 101 
results, we successfully applied NFAP2 alone and in combination with FLC in an in vivo 102 
murine VVC model system. 103 
 104 
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Results 105 
In vitro susceptibility. In our previous work we observed that the antifungal efficacy and the 106 
minimal inhibitory concentration (MIC) of NFAP2 depend on the applied test medium and the 107 
investigated Candida strain (10, 12). One of the major virulence factors of C. albicans is the 108 
ability to form a biofilm, which shows less susceptibility or intrinsic resistance to 109 
conventional antifungal agents. Furthermore, the formation of biofilm plays a role in the 110 
colonization of mucosal surfaces (14). Hence, we determined the exact MICs of FLC and 111 
NFAP2 for planktonic and sessile biofilm cells of C. albicans 27700 in RPMI 1640 medium 112 
simulating the human extracellular environment in composition. MIC values of FLC proved 113 
to be 16 μg/ml and 512 μg/ml for planktonic and sessile cell population, respectively. 114 
According to susceptibility breakpoints (15), C. albicans 27700 is resistant to FLC. Both cell 115 
types showed the same susceptibility to NFAP2 with MICs of 800 μg/ml. It is noteworthy, 116 
that 400 μg/ml NFAP2 already caused >50% decrease in turbidity and metabolic activity for 117 
planktonic cells. At this concentration NFAP2 was inactive against the biofilm, significant 118 
decrease in turbidity and in metabolic activity was not observed. 119 
Anti-Candida mechanism. Our previous observations applying the membrane impermeant, 120 
red-fluorescent nuclear and chromosome stain propidium-iodide (PI) already suggested the 121 
prompt plasma membrane disruption ability of NFAP2 on yeast cells as the key factor of the 122 
antifungal effect (10, 12), but the exact mechanism for the membrane disruption has not been 123 
investigated yet. First, we quantified the number of disrupted cells by fluorescence-activated 124 
cell sorting (FACS) analysis. It revealed that 38.20±3.12% (p = 0.00007) of the FLC-resistant 125 
C. albicans 27700 cells have a PI-positive phenotype after 24 hours of NFAP2-treatment at 126 
the MIC compared to the untreated control (3.26±1.72%) (Fig. S1 in the supplemental 127 
material). Scanning electron microscopy (SEM) images showed that NFAP2 forms pores in 128 
the plasma membrane, causing the loss of cell content which finally results in cell death (Fig. 129 
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1). Several different molecular mechanisms of membrane disruption were proposed for 130 
antimicrobial peptides and proteins previously. Many of such mechanisms (including pore 131 
formation) involve significant conformational changes and/or oligomerization of the 132 
membrane-acting proteins (16-18). This conformational change can be detected by electronic 133 
circular dichroism spectroscopy (ECD) (19). We observed that the ECD spectrum of NFAP2 134 
in the presence of yeast cells is similar to that of the pure aqueous NFAP2 solution and 135 
demonstrates previously described spectral contributions emerging from β-conformation (200 136 
nm, 212 nm) and disulfide bridges (228 nm) (Fig. 2) (12). The presence of C. albicans 27700 137 
cells did not induce any change in the secondary structure of the protein within 24 hours of 138 
incubation. However, the number of colony forming units (CFU) decreased significantly (p = 139 
000062), from 6.10±0.54 × 10
6
 cells/ml to 2.49±0.34 ×10
6
 cells/ml in the samples, during the 140 
24 hours time frame of ECD measurements. This suggests that while 100 mg/ml NFAP2 141 
exposure results in notable cell death, mechanisms of action accompanied by large scale 142 
structural changes can be ruled out for NFAP2. 143 
In vitro cytotoxicity. In silico prediction showed high binding affinity of NFAP2 to the 144 
human serum albumin (HSA) (ΔG = -12.16 kcal/mol, Kd = 1.21e-09 M) (20), hence its 145 
systemic application as antifungal drug is debatable. However, NFAP2 is considered as a 146 
potential candidate for a novel topical antifungal agent, and the most possible therapeutic 147 
application is the treatment of superficial candidiasis (12). To verify this suggestion, it is 148 
necessary to elucidate the cytotoxic potential of the protein on HKC and HDF as the 149 
predominant cell type in the epidermis, and the most common cells of connective tissue 150 
synthesizing the extracellular matrix and collagen, respectively. In vitro viability staining of 151 
primary HKCs and HDFs with PI after exposure to NFAP2 for 24 hours revealed no change 152 
in the number of PI-positive cells even after treatment with twice the MIC (Fig. S2 in the 153 
supplemental material). 154 
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In vivo application. Based on the observed in vitro MIC values, NFAP2 is considered as a 155 
monotherapeutic agent in the treatment of VVC caused by FLC-resistant strains. In vitro data 156 
already suggested that NFAP2 could interact synergistically with FLC against C. albicans 157 
(12), hence the in vivo antifungal effect of NFAP2-FLC combination was also investigated to 158 
reveal a possible FLC-resistance reversion. Results of the in vivo experiments are shown in 159 
Fig. 3. The single 35 mg/kg and the daily 5 mg/kg doses of FLC could not reduce 160 
significantly (p > 0.05) the vaginal fungal burden compared to untreated mice. In comparison 161 
with the untreated group of animals, 800 μg/ml/day NFAP2 regimens alone or in combination 162 
with 5 mg/kg/day FLC caused significant reduction (p ≤ 0.05) in the number of living C. 163 
albicans cells from vaginal tissue. This reduction was more prominent when NFAP2 was 164 
applied in combination with FLC (p = 0.0017) than as a monotherapeutic agent (p = 0.0177). 165 
Furthermore, the yeast cell number decreasing activity of NFAP2-FLC combination proved to 166 
be significantly more effective than that of FLC alone (p = 0.0001 and p = 0.0084 compared 167 
to 35 mg/kg single and 5 mg/kg daily dose, respectively). All significance values are indicated 168 
in Table S2 in the supplemental material. 169 
Histology. Grocott-Gömöri methenamine-silver nitrate (GMS) staining revealed the presence 170 
of yeast and pseudohyphal form of Candida cells in the vaginal tissues of infected mice (Fig. 171 
4A-D). However, decrease in the fungal cell number was observable when the animal was 172 
treated with NFAP2 or NFAP2-FLC combination (Fig. 4C and D) in comparison with the 173 
untreated and FLC-treated groups (Fig. 4A and B). Inflammatory reaction indicated by 174 
neutrophilic granulocytes was observable in all samples stained with hematoxylin-eosin 175 
(H&E) (Fig. 4), but it was more moderate in NFAP2 and NFAP2+FLC treated animals (Fig. 176 
4C and D) than in untreated and FLC-treated groups (Fig. 4A and B). The vaginal 177 
inflammation detected in uninfected mice could have been the consequence of the prior 178 
estradiol-valerate treatment (Fig. 4E) (21). 179 
 o
n
 N
ovem
ber 27, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
9 
 
 180 
Discussion 181 
crAFPs (such as the NFAP2-related Aspergillus giganteus antifungal protein, AFP; and 182 
Penicillium chrysogenum antifungal protein, PAF) are of particular interest in the fight against 183 
fungal infections as they show in vitro growth inhibitory activity against fungal pathogens, 184 
and they are non-toxic to mammalian cells (22, 23). However, their in silico predicted strong 185 
binding ability to HSA (ΔG = -13.52 kcal/mol, Kd = 1.22e-10 M for AFP, and ΔG = -11.09 186 
kcal/mol, Kd = 7.33e-09 M for PAF) diminishes the expectations for systemic application 187 
(20). In this study we provide for the first time information about the in vivo antifungal 188 
efficacy of a crAFP as a topical agent in the treatment of mucosal infection caused by C. 189 
albicans; an opportunistic human pathogenic yeast. 190 
NFAP2 represents a novel, phylogenetically distinct group of crAFPs, and shows a unique 191 
high anti-yeast activity in vitro (10, 12). The in vivo animal model experiments in our study 192 
required the determination of the in vitro MIC of NFAP2 against the applied microorganism 193 
for the infection, and the investigation of the cell-killing ability under clinically approved test 194 
conditions. Previous studies demonstrated that in vitro antifungal efficacy of crAFPs highly 195 
depends on the ion strength of the test medium (24, 25). According to this, NFAP2 shows 196 
higher MICs on the same Candida strain in the highly cationic RPMI 1640 than in a low 197 
cationic medium (12). This feature is not exclusive to NFAP2; relative high MICs were 198 
observed for PAF (26) and NFAP (27), when their activity was tested against different human 199 
pathogenic filamentous fungi in RPMI 1640. RPMI 1640 is a standard medium recommended 200 
by CLSI for clinical susceptibility tests, and it simulates the composition of human 201 
extracellular environment. Our results showed that both planktonic and sessile biofilm cells of 202 
the tested FLC-resistant C. albicans isolated from human VVC are susceptible to NFAP2 in 203 
this medium. Biofilm formation of C. albicans isolates from hospitalized patients is directly 204 
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related to the virulence. C. albicans is more tolerant to antifungal drugs in this form than the 205 
planktonic cells, contributing to the pathogenesis of superficial and systematic candidiasis 206 
(28). Parallel to this observation, the sessile biofilm cells of the involved C. albicans isolate 207 
were less susceptible to FLC and NFAP2 than the planktonic cells. The applied CLSI M27-208 
A3 method recommends 10
3
 cells/ml as inoculum for the MIC determination. However, the 209 
detected MIC based on this method does not guarantee the same inhibitory efficacy against 210 
higher cell numbers (29). After 24 hours of incubation, around one-third of the yeast cells 211 
were killed when the MIC of NFAP2 was applied against 10
7
 cells/ml (Fig. S1 in the 212 
supplemental material). This amount represents the yeast cell number that was used for the 213 
vaginal infection in the in vivo animal model experiments. 214 
The potential in vivo application of a drug candidate in the treatment of mycotic infections 215 
highly depends on its fungal selectivity, namely the exerted antifungal mechanism on the 216 
pathogenic fungi, and the cytotoxic effects on the host cells. Antifungal plant defensins with 217 
similar features to crAFPs (such as disulfide-bond stabilized tertiary structure, positive net 218 
charge, and amphipathic surface) are non-toxic to human cells, and they bind to specific 219 
fungal membrane components of yeast cell causing membrane permeabilization and/or 220 
disruption (30). These actions may require the conformational change of the antifungal plant 221 
defensin (31). Our results show that the yeast cell killing activity of NFAP2 is realized by 222 
pore formation in the fungal plasma membrane without any changes in the secondary 223 
structure (Fig. 1 and Fig. 2). These observations together with the lack of in vitro toxicity 224 
(even at twice the MIC, Fig. S2 in the supplemental material) on primary HKCs and HDFs 225 
suggest the fungal selectivity of NFAP2 to yeast cells. Furthermore, based on the reported 226 
antifungal mode of action of membrane destructive plant defensins (30), we hypothesize that 227 
the presence of a fungal-specific plasma membrane target may be involved in the antifungal 228 
mechanism of NFAP2. To reveal the nature of this target awaits further investigations. 229 
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Membrane disrupting antifungal peptides are considered as a potential new class of 230 
antifungals to treat FLC‐resistant VVC, however, their in vivo antifungal potency in this 231 
infection and their impact on the host body have not been tested yet (32, 33). Our above 232 
discussed in vitro results proposed the in vivo therapeutic potency of NFAP2 as a topical 233 
agent in the treatment of VVC caused by FLC-resistant C. albicans. Considering the fact that 234 
biofilm formation is involved in the C. albicans colonization of mucosal surfaces (14), one 235 
dosage of NFAP2 in the in vivo murine VVC model corresponded to the determined in vitro 236 
MIC. However, total recovery from the infection was not reached at this dosage (Fig. 4C). 237 
Instead, the daily application of NFAP2 significantly decreased the cell number of the FLC-238 
resistant C. albicans strain in the vagina in contrast to FLC (Fig. 3). This result proves the 239 
potential effectiveness of NFAP2 monotheraphy in the treatment of superficial yeast 240 
infections. Until today the in vivo applicability of crAFPs as antifungal agents was 241 
investigated only with PAF (34, 35). Since PAF effectively inhibits the growth of human 242 
pathogenic filamentous fungi (23), its therapeutic potential was tested by Palicz et al. (2016) 243 
in a murine pulmonary aspergillosis model (35). Twice a day intraperitoneal application of 244 
PAF was not able to overcome the fungal invasion finally, however, it could prevent the 245 
spread of Aspergillus fumigatus in the lung tissue in the first days and prolonged the survival 246 
of the animals with one day (35). 247 
Before the present study, the described in vitro synergistic interaction between NFAP2 and 248 
FLC against Candida isolates already suggested the polytherapeutic potential of the protein 249 
(12). Our results from in vivo murine VVC model experiments clearly corroborates that the 250 
combined application of NFAP2 and FLC is more effective against the involved FLC-251 
resistant C. albicans isolate than the treatment with the two compounds alone (Fig. 3). This 252 
result suggests a positive in vivo interaction between them in the vaginal tissue and the 253 
reversion of FLC-resistance. Similarly to our findings a better outcome was observed in a 254 
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murine pulmonary aspergillosis model when PAF was combined with amphotericin B 255 
(AMB), namely the PAF-AMB combination prolonged the survival of the animals and 256 
decreased the lung injury score compared to their monotherapeutic application (35). 257 
Intranasal application of PAF in mice did not alter the important physiological parameters of 258 
the animals and did not cause morphological changes in the affected organs. Furthermore 259 
inflammatory response of the skin following PAF application was not observed (34). Based 260 
on these and other in vivo toxicity results PAF is considered as a safely applicable antifungal 261 
compound (34, 35). Our histological examinations signed that NFAP2 could also be safely 262 
used in topical therapy since it did not cause morphological alterations and serious 263 
pathological reactions of the vaginal and vulvar tissues (Fig. 4), and did not change the 264 
macromorphology of the affected organs (data not shown). The presence of neutrophilic 265 
granulocytes after NFAP2 application indicates that they are recruited to the site of the 266 
infection to kill the fungal pathogen (Fig. 4C and D), and NFAP2 does not inhibit this 267 
process. However, the fungal infection was still present in the vagina after treatment with 268 
NFAP2 or NFAP2-FLC combination (Fig. 4C and D); significant decrease in the viable C. 269 
albicans cell number was observed in comparison with the untreated group of animals (Fig. 270 
3). As NFAP2 did not show any cytotoxic effects even at twice the MIC (Fig. S2 in the 271 
supplemental material), the protein should be administered in higher doses than the in vitro 272 
MIC dose applied in our experiments to reach the full recovery from the infection. 273 
Considering our in vivo results presented in this study and the fact that recombinant NFAP2 274 
can be produced in high amount by the GRAS microorganism P. chrysogenum (12), this 275 
protein provides a feasible base to develop a novel topical agent in the treatment of superficial 276 
candidiasis caused by drug-resistant Candida strains. 277 
 278 
Materials and methods 279 
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Strains and media. The previously well-characterized FLC-resistant and biofilm-forming C. 280 
albicans 27700 strain isolated from human vulvovaginal candidiasis was used in the 281 
experiments (36). It was maintained on yeast extract glucose agar slants with KH2PO4 282 
(YEGK) at 4 °C. Primary HKC and HDF cells were isolated and grown in CellnTec basal 283 
(CnT-BM.1; CellnTec, Bern, Switzerland) and R10 medium, respectively, as described 284 
previously (37). CFU was determined on yeast extract peptone dextrose (YPD) and 285 
Sabouraud dextrose (SD) agar plates. In vitro antifungal susceptibility tests were performed in 286 
RPMI 1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 0.03% (w/v) 287 
L-glutamine and buffered to pH 7.0 with 0.165 M 4-morpholinopropanesulfonic acid (Sigma-288 
Aldrich, St Louis, MO, USA). Media compositions are listed in Table S1 in the supplemental 289 
material. 290 
Protein production and purification. Recombinant NFAP2 was produced by Penicillium 291 
chrysogenum and purified by cation-exchange chromatography as described before (12). To 292 
exclude the effects of any contaminating compounds during the experiments, NFAP2 was 293 
further purified by semipreparative reversed-phase high performance liquid chromatography 294 
(RP-HPLC) on a Shimadzu-Knauer apparatus (Kyoto, Japan) to reach 100% purity (Fig. S3 in 295 
the supplemental material). The following solvent system was applied: (A) 0.1% (v/v) 296 
trifluoroacetic acid (TFA), (B) 80% (v/v) acetonitrile, 0.1% (v/v) TFA. Linear gradient from 0 297 
to 30% (v/v) solvent (B) over 60 min was used at the flow rate of 4 ml/min. Peaks were 298 
detected at 220 nm. Purity of the NFAP2 was checked by analytical RP-HPLC on an Agilent 299 
1200 Series HPLC instrument (Agilent Technologies, Santa Clara, CA, USA) using the same 300 
solvent system as for purification from 15 to 30% (v/v) solvent (B) over 15 min at 1 ml/min 301 
flow rate. 302 
In vitro susceptibility testing. Susceptibility testing of C. albicans 27700 planktonic cells to 303 
FLC and NFAP2 was performed using the broth microdilution method in accordance with the 304 
 o
n
 N
ovem
ber 27, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
14 
 
CLSI approved standard M27-A3 protocol (38). The final drug concentrations ranged from 25 305 
to 1600 μg/ml and from 2 to 1024 μg/ml for NFAP2 and FLC (Sigma-Aldrich, St Louis, MO, 306 
USA), respectively. Susceptibility of sessile biofilm C. albicans 27700 cells to FLC and 307 
NFAP2 was determined by 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-308 
carboxanilide (XTT) reduction assay following the protocol described in Pierce et al. (2008) 309 
(39) with slight modifications. Briefly, aliquots of 100 μl of standardized C. albicans 27700 310 
suspension (1 × 10
6
 CFU/ml) in RPMI 1640 were inoculated in wells of polystyrene flat-311 
bottom 96-well microtiter plates (TPP, Trasadingen, Switzerland) and incubated statically for 312 
24 hours at 37 C to allow the biofilm-formation. The one-day-old biofilms were washed 313 
three times with 200 μl saline in order to remove the non-attached fungal cells, then the final 314 
concentration of NFAP2 (25-1600 μg/ml), and FLC (8-512 μg/ml) was pipetted onto them. 315 
After 24 hours incubation at 37 C, metabolic activity was quantified. Briefly, wells were 316 
filled with 100 μl of 0.5 mg/ml XTT / 1 μM menadione solution (both from Sigma-Aldrich, St 317 
Louis, MO, USA), and then the plates were covered with aluminum foil and incubated for 2 318 
hours at 37°C. After this incubation period, the absorbance (A492) of 80 μl supernatant was 319 
measured in flat-bottom 96-well microtiter plates. MIC for planktonic and sessile biofilm cells 320 
was defined as the lowest protein or drug concentration at which ≥90% reduction was 321 
detected in turbidity and metabolic activity in comparison with the untreated control. The 322 
percentage change in turbidity and metabolic activity was calculated on the basis of 323 
absorbance (A492) as 100% × (Awell – Abackground)/(Adrug-free well – Abackground). Abackground 324 
corresponds to the absorbance of fungal-free and drug-free wells. Susceptibility of C. albicans 325 
27700 was tested in three independent experiments. 326 
FACS. FACS, SEM and ECD investigations (later) were performed on mid-log phase C. 327 
albicans 27700 cells grown up in RPMI-1640 medium at 30 °C under continuous shaking at 328 
160 rpm. The proportion of the dead cells after NFAP2-treatment was determined by applying 329 
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the membrane impermeant, red-fluorescent nuclear and chromosome stain PI (Sigma-Aldrich, 330 
St Louis, MO, USA). The yeast cells (1 × 10
7
 cells) were incubated in the presence of NFAP2 331 
at MIC (800 μg/ml) in RPMI 1640 for 24 hours at 30 °C with continuous shaking at 160 rpm. 332 
After incubation, cells were collected by centrifugation (17,000 × g, 2 min) and washed with 333 
PBS (pH 7.4), then stained with 5 μg/ml PI for 10 min at room temperature in the dark, and 334 
finally washed again with PBS (pH 7.4), before resuspending them in PBS (pH 7.4). The 335 
number of PI-positive cells was counted and analyzed using FlowSight Imaging Flow 336 
Cytometer (Amins, Merck Millipore, Billerica, MA, USA) and the related Image Data 337 
Exploration and Analysis Software (IDEAS, Amins, Millipore, Billerica, MA, USA). Twenty 338 
thousand cells were screened, and the FACS analysis was repeated in three independent 339 
experiments. Cells treated with 70% (v/v) ethanol for 10 min at 4 °C were used as positive 340 
staining control. Untreated cells (RPMI 1640 without NFAP2) were used as natural death 341 
control. FACS analyses were achieved in three independent experiments. 342 
SEM. C. albicans 27700 cells (1×10
7
 cells) were treated with MIC of NFAP2 (800 μg/ml) as 343 
described before for the FACS analysis. Untreated cells served as positive phenotype control. 344 
Eight microliters of the cell suspensions in PBS were spotted on a silicon disc coated with 345 
0.01% Poly-L-Lysine (Merck Millipore, Billerica, MA, USA), then the cells were fixed by 346 
gently adding 2.5% (v/v) glutaraldehyde and 0.05 M cacodylate buffer (pH 7.2) in PBS (pH 347 
7.4) for one hour. After that, the discs were washed twice with PBS (pH 7.4) and dehydrated 348 
with a graded ethanol series (30%, 50%, 70%, 80%, and 100% (v/v) ethanol, each for 15 min 349 
at room temperature). The samples were dried with Quorum K850 critical point dryer 350 
(Quorum Technologies, Laughton, East Sussex, UK), followed by 12 nm gold coating and 351 
observed under a JEOL JSM-7100F/LV scanning electron microscope (JEOL Ltd, Tokyo, 352 
Japan). 353 
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ECD spectroscopy. C. albicans 27700 cells were washed two times and resuspended in 354 
ddH2O or in aqueous solution of NFAP2 (100 μg/ml) in a final concentration of 10
7
 cells/ml. 355 
ECD spectroscopic measurements of these samples and an aqueous solution of NFAP2 (100 356 
μg/ml) were performed in the 185-260 nm wavelength range using a Jasco-J815 357 
spectropolarimeter (JASCO, Tokyo, Japan). Spectra were collected at 25 °C with a scan speed 358 
of 100 nm/s using a 0.1 cm pathlength quartz cuvette. Spectra presented are accumulations of 359 
10 scans for each sample. Spectrum acquisitions were done after 0 and 24 hours of incubation 360 
of the samples at 30 °C under continuous shaking at 160 rpm. After the spectroscopic 361 
measurements, CFU of the NFAP2-treated and untreated samples was determined. This 362 
experiment was repeated twice. 363 
Determination of CFU. Following ECD measurements, cells were collected by 364 
centrifugation (17,000 × g, 2 min) and washed two times with YPD medium then ten-fold 365 
serial dilutions were prepared in five steps in one milliliter YPD. 100 µl cell suspensions from 366 
the last three steps were spread on YPD agar plates in three replicates. Colony number was 367 
counted after incubation for 24 hours at 30 °C. 368 
In vitro cytotoxicity assay. Fluorescence viability staining was performed on primary HKC 369 
and HDF cells grown in chambered cell culture slides (Falcon, Corning Life Sciences, 370 
Tewksbury, MA, USA). The cells (4 × 10
3
 cells/well) were seeded and grown until they 371 
reached 70-80% confluence at 37 °C and 5% CO2, then NFAP2 in the concentration range 372 
between 400-1600 μg/ml was added and the plates were incubated for 24 hours under the 373 
same conditions. After the incubation period, the cells were washed with phosphate buffered 374 
saline (PBS, pH 7.4) and the fluorescent dye PI (1 μg/ml) and 2′-(4-hydroxyphenyl)-5-(4-375 
methyl-1-piperazinyl)-2,5′-bi-1H-benzimidazole trihydrochloride hydrate (Hoechst, 1 μg/ml; 376 
Sigma-Aldrich, St Louis, MO, USA) were added for 10 minutes in the dark. Untreated cells 377 
were used as living controls, and 50% ethanol-treated (for 10 minutes) as dead control. The 378 
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cells were washed three times with PBS (pH 7.4) and observed with a Zeiss Axioplan 379 
fluorescence microscope (Zeiss, Oberkochen, Germany), equipped with an Axiocam mono 380 
microscope digital camera (Zeiss, Oberkochen, Germany), excitation/emission filters 365/420 381 
nm for blue fluorescence and 546/590 or 565/620 nm for red fluorescence. Image acquisition 382 
and editing was done with ZEN 2 (blue edition) microscope software (Zeiss, Oberkochen, 383 
Germany) and GIMP 2 (GNU Image Manipulation Program, version 2.8.10). The study with 384 
primary HKC and HDF was carried out in accordance with the recommendations of the Ethics 385 
Committee of the Medical University of Innsbruck (Innsbruck, Austria). The protocol was 386 
approved from the Ethics Committee of the Medical University of Innsbruck. All subjects 387 
gave written informed consent in accordance with the Declaration of Helsinki. The in vitro 388 
cytotoxicity assay was repeated twice. 389 
In vivo murine vulvovaginitis model. Groups of ten BALB/c immunocompetent female 390 
mice (weight: 20-22 g) were used in this study. The animals were maintained in accordance 391 
with the Guidelines for the Care and Use of Laboratory Animals (40); experiments were 392 
approved by the Animal Care Committee of the University of Debrecen (permission no.: 393 
12/2014). Mice were administered 50 μl subcutaneous estradiol-valerate (10 mg/ml prepared 394 
in sesame seed oil) 72 hours prior to infection to establish the VVC (41, 42). In accordance 395 
with our previous studies, mice were challenged intravaginally with 1-1.2 × 10
7
 CFU of C. 396 
albicans 27700 in final volume of 25 μl (36, 42). Mice were divided into the following five 397 
groups: i) untreated control, ii) 800 μg/ml/day NFAP2, iii) 35 mg/kg/once FLC which 398 
corresponds to the normal human dose of 150 mg based on 24h-AUC value (43), iv) 399 
5mg/kg/day FLC, and v) 800 μg/ml/day NFAP2 + 5 mg/kg/day FLC. All treatments were 400 
started after 24 hours of the infection when the presence of C. albicans biofilm had become 401 
evident on the murine vaginal mucosa (44). FLC treatment was given intraperitoneally at a 402 
volume of 0.5 ml, while NFAP2 was administered intravaginally at a volume of 25 μl and one 403 
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hour after the FLC treatment when it was applied in combination with FLC. Untreated control 404 
mice were given 0.5 ml and/or 25 μl physiological saline for intraperitoneally and 405 
intravaginally, respectively. At four days postinfection, fungal vagina burden was determined 406 
after sacrificing of animals. Whole vaginae were excised, weighed and homogenized in one 407 
milliliter saline. Aliquots of 100 μl of the undiluted and diluted (1:10) homogenates were 408 
plated onto SD agar plates. The plates were incubated for 48 hours at 35 C, and then the 409 
CFUs were determined. The lower limit of detection was 50 CFU/g/tissue. All animal 410 
experiments were repeated two times, and five animals were involved in each group in each 411 
treatment. 412 
Histology. Vaginae of different but identically treated mice were involved in histological 413 
investigations as those described above. The histopathological examination and histochemical 414 
staining were performed on routine formalin fixed, paraffin embedded, mouse vaginal tissues. 415 
Serial 4 μm thick sections were cut from paraffin blocks and routine GMS and H&E stains 416 
were performed (45). 417 
In silico analysis. The binding ability of NFAP2 to HSA (UniProt IDs: A0A1D0CRT2 and 418 
P02768, respectively; 46) was predicted by the PPA-Pred2 (Protein-Protein Affinity 419 
Predictor) server (20). 420 
Statistical analyses. CFU data after ECD experiments were analyzed using Microsoft Excel 421 
2010 software (Microsoft,Edmond, WA, USA), and the two sample t-test was used to 422 
determine the significance values. Vaginal burden was analyzed using Kruskal-Wallis test 423 
with Dunn’s post-test for multiple comparisons using the software GraphPad Prism version 424 
6.05 (GraphPad Software, San Diego, CA, USA). Significance was defined as p < 0.05, based 425 
on the followings: * : p ≤ 0.05, ** : p ≤ 0.005, *** : p ≤ 0.0001. 426 
 427 
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Supplemental material for this article may be found at 429 
SUPPLEMENTAL FILE 1, PDF file, 0.7 MB. 430 
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Figure legends 579 
 580 
FIG 1 Scanning electron microscopy of C. albicans 27700 cells after incubation in (A and B) 581 
RPMI 1640 medium, and (C and D) in RPMI 1640 medium supplemented with 800 μg/ml 582 
NFAP2 for 24 hours at 30 °C with continuous shaking at 160 rpm. Framed regions in (A and 583 
C) are shown at higher magnification in (B and D) respectively. Arrows indicate the pore 584 
formation in the cell envelop and the loss of cell content after exposure to NFAP2. Scale bars, 585 
1 μm. 586 
 587 
FIG 2 ECD spectra of NFAP2 in ddH2O (blue), and in the presence of C. albicans cells 588 
immediately after exposure (red) to, and after 24 hours of incubation (green) with 100 µg/ml 589 
NFAP2 at 30 °C with continuous shaking at 160 rpm. 590 
 591 
FIG 3 In vivo efficacy of NFAP2, FLC and their combination in murine vulvovaginitis 592 
model. The bars represent the mean ± SEM (standard error of mean) of the vaginal tissue 593 
burden of BALB/c mice intravaginally infected with FLC-resistant C. albicans 27700 isolate. 594 
Significant differences (p-values) between the CFU numbers were determined based on the 595 
comparison with the untreated control. Other significance values existing between the 596 
different treatments are presented in Table S2 in the supplemental material. Level of 597 
significant differences are indicated at p ≤ 0.05 (*), p ≤ 0.005 (**). 598 
 599 
FIG 4 Histological investigation of vaginal tissue from mice suffering from vulvovaginal 600 
candidiasis (A) without and with topical (B) 5 mg/kg/day FLC, (C) 800 µg/ml NFAP2, and 601 
(D) combined 5 mg/kg/day FLC + 800 µg/ml NFAP2 treatments. (E) Vaginal tissue of 602 
uninfected mice. Vaginal tissues were stained with GMS (left) and H&E (right). Blue arrows 603 
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indicate the presence of C. albicans 27700 cells (left images) and neutrophilic granulocytes 604 
(right images). Scale bars, 50 µm. 605 
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